Affinage

Showing KLF10 — TIEG1 is a alias.

KLF10

Krueppel-like factor 10 · UniProt Q13118

Length
480 aa
Mass
52.6 kDa
Annotated
2026-06-10
100 papers in source corpus 51 papers cited in narrative 51 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

KLF10 (TIEG1) is a TGF-β-inducible Krüppel-like zinc finger transcription factor that translates TGF-β/BMP signaling into transcriptional programs governing cell fate, immune tolerance, bone formation, and hepatic metabolism (PMID:9153278, PMID:10816551, PMID:15657444). Its zinc finger domain binds GT/GC-rich elements (consensus 5'-GGTGTG-3' and Sp1 sites) in target promoters (PMID:12804117), and three conserved repressor domains outside the DNA-binding region mediate transcriptional repression (PMID:10506214). KLF10 represses targets — including Smad7, EGFR, SLUG/SNAI2, and IL-9 — by occupying their promoters and recruiting HDAC1 to strip activating histone acetylation (PMID:22025675, PMID:28249899, PMID:28108300, PMID:35440172), and it engages the histone demethylase JARID1B/KDM5B and the Sin3 complex for repression while switching to activation through association with the acetyltransferase PCAF (PMID:20863814, PMID:24944246). As an activator it directly transactivates Runx2 and Osterix to drive osteoblast differentiation (PMID:21559363, PMID:26801561) and binds the TGF-βRII promoter in T cells and macrophages to reinforce TGF-β/Smad signaling (PMID:25472963, PMID:26472224). In immune regulation, KLF10 is essential for TGF-β-driven Treg development and suppression of inflammation, acting through a TGF-β1/Foxp3 positive-feedback loop and cooperating with the E3 ligase Itch (PMID:18278048, PMID:19602726, PMID:33378664). In liver, KLF10 is a circadian-clock-controlled gene that represses Bmal1 and gluconeogenic/lipogenic programs, linking the clock to glucose and lipid homeostasis (PMID:20070857, PMID:20385766, PMID:28836014, PMID:34869587). KLF10 stability and localization are set post-translationally by RAF-1/PIN1-driven degradation at Thr93, AMPK-mediated stabilization at Thr189, and Tyk2-mediated Tyr179 phosphorylation that promotes K27-ubiquitination and cytoplasmic retention (PMID:21471442, PMID:23994618, PMID:34869587). Human KLF10 missense mutations are linked to hypertrophic cardiomyopathy through gain of PTTG1 promoter activation (PMID:22234868).

Mechanistic history

Synthesis pass · year-by-year structured walk · 21 steps
  1. 1997 Medium

    Established KLF10 as a functional downstream effector of TGF-β rather than a passive marker, by showing its overexpression alone drives apoptosis in TGF-β-sensitive epithelial cells.

    Evidence Stable overexpression in PANC1 pancreatic cells with apoptosis readout

    PMID:9153278

    Open questions at the time
    • Did not define direct transcriptional targets driving apoptosis
    • Single cell type; mechanism of cell-death induction unresolved
  2. 1999 High

    Defined the molecular grammar of KLF10 as a repressor by mapping three conserved repression domains separate from the DNA-binding region.

    Evidence Mutagenesis and GAL4 reporter assays comparing TIEG1 and TIEG2

    PMID:10506214

    Open questions at the time
    • Did not identify the corepressors recruited by each domain
    • Domains defined in heterologous GAL4 context, not native promoters
  3. 1999 High

    Resolved the apoptotic mechanism downstream of KLF10 as mitochondrial/ROS-dependent, showing antioxidant rescue blocks death.

    Evidence ROS, mitochondrial potential, caspase, and trolox-rescue assays in Hep3B cells

    PMID:10573529

    Open questions at the time
    • Did not connect ROS generation to a direct transcriptional target
  4. 2003 High

    Defined the DNA-binding specificity of KLF10, anchoring all subsequent promoter-occupancy claims to a GT-rich core motif.

    Evidence SELEX-like in vitro selection and mutational analysis of the zinc finger domain

    PMID:12804117

    Open questions at the time
    • In vitro binding only; in vivo genome-wide occupancy not mapped
  5. 2005 High

    Demonstrated a physiological bone role in vivo, showing KLF10-null osteoblasts fail BMP2-induced mineralization and dysregulate the RANKL/OPG axis.

    Evidence TIEG1 KO calvarial osteoblast culture, mineralization assay, osteoclast co-culture rescue

    PMID:15657444

    Open questions at the time
    • Direct promoter targets in osteoblasts not yet identified at this stage
  6. 2008 High

    Established KLF10 as essential for TGF-β-driven Treg development and immune suppression, and identified Itch as a partner mediating non-proteolytic K63 ubiquitination supporting Foxp3 induction.

    Evidence Co-IP, ubiquitination assays, Itch-/- and TIEG1-/- T cells, in vivo airway inflammation

    PMID:18278048

    Open questions at the time
    • Site of K63 ubiquitination on KLF10 not mapped
    • How ubiquitination mechanistically enhances Foxp3 transactivation unclear
  7. 2008 High

    Defined a TGF-β1/Foxp3 positive feedback loop driven by KLF10 promoter transactivation, explaining the Treg suppressor phenotype mechanistically.

    Evidence KLF10 KO CD4+ T cell studies, promoter transactivation, Th1/Th2 profiling, atherosclerosis model

    PMID:19602726

    Open questions at the time
    • Cofactors switching KLF10 to activator mode at these promoters not yet defined
  8. 2010 High

    Placed KLF10 within the circadian clock and hepatic metabolism, showing it is a CLOCK-BMAL1 target that in turn represses Bmal1 and Pepck to control glucose homeostasis.

    Evidence KLF10/Bmal1 KO mice, ChIP at Klf10 promoter, circadian bioluminescence reporters, Pepck reporter, glucose production assay

    PMID:20070857 PMID:20385766

    Open questions at the time
    • Whether KLF10 repression of Bmal1 versus activation of metabolic genes uses distinct cofactors not resolved
  9. 2010 Medium

    Identified the chromatin-modifying machinery for KLF10 repression — the JARID1B/KDM5B demethylase binds the repression domains and augments Smad7 silencing.

    Evidence Co-IP, domain mapping, Smad7 reporter with JARID1B gain/loss

    PMID:20863814

    Open questions at the time
    • H3K4 demethylation at the Smad7 promoter inferred from reporter data, not directly measured
    • Single lab
  10. 2011 High

    Established post-translational control of KLF10 function, with Tyk2-mediated Tyr179 phosphorylation triggering K27-ubiquitination and cytoplasmic retention that disables Treg development under inflammatory IL-6.

    Evidence Phosphorylation/ubiquitination assays, nuclear fractionation, Treg assays, TRAMP-C2 tumor model

    PMID:21471442

    Open questions at the time
    • Identity of the K27-linkage E3 ligase not established
  11. 2011 High

    Showed KLF10 acts both as direct activator (Runx2, p21) and HDAC1-recruiting repressor (EGFR, BI-1), defining its dual transcriptional outputs in bone and cancer.

    Evidence ChIP/Co-IP at Runx2 and EGFR promoters, HDAC1 complex Co-IP, ChIP-chip/EMSA at BI-1, KO rescue and xenograft models

    PMID:21262377 PMID:21559363 PMID:22025675

    Open questions at the time
    • The determinants that select activation vs repression at a given promoter not defined
  12. 2012 Medium

    Connected KLF10 to human disease, showing HCM-associated missense mutations aberrantly raise PTTG1 promoter activity and PTTG1 protein in patient cardiac tissue.

    Evidence Site-directed mutagenesis, PTTG1 promoter luciferase, immunohistochemistry of HCM cardiac tissue

    PMID:22234868

    Open questions at the time
    • Causality between mutation and cardiomyopathy not demonstrated by genetic models
    • Single promoter assayed
  13. 2013 High

    Defined a RAF-1/PIN1 degradation axis: phosphorylation at Thr93 creates a pThr93-Pro motif recognized by PIN1 isomerase that drives KLF10 turnover.

    Evidence In vitro kinase assay, yeast two-hybrid, Thr93 mutagenesis, cycloheximide chase

    PMID:23994618

    Open questions at the time
    • E3 ligase coupling PIN1 isomerization to degradation not identified
  14. 2014 High

    Revealed the molecular switch between KLF10 repression and activation at FOXP3 — an NH2-terminal Sin3-interacting domain restrains activation, and its inactivation enables PCAF recruitment.

    Evidence Domain mutagenesis, Co-IP with PCAF and Sin3-HDAC, ChIP, genome-integrated reporter, primary lymphocytes

    PMID:24944246

    Open questions at the time
    • Signals that physiologically toggle the Sin3-vs-PCAF balance not identified
  15. 2015 High

    Extended the TGF-βRII activation mechanism across immune lineages, showing KLF10 promotes TGF-βRII transcription via H3 acetylation to maintain anti-inflammatory macrophage and CD8 T cell signaling.

    Evidence ChIP and H3-acetylation assays at TGF-βRII promoter, KO T cells/macrophages, cytokine profiling, adoptive transfer and viral infection models

    PMID:25472963 PMID:26472224

    Open questions at the time
    • The acetyltransferase recruited at TGF-βRII not pinpointed
  16. 2015 Medium

    Demonstrated KLF10 is itself druggable, with CADD-identified small molecules binding the second zinc finger to block DNA binding and Treg conversion.

    Evidence Virtual screening, DNA-binding inhibition assays, Treg conversion assay

    PMID:25581017

    Open questions at the time
    • No co-crystal structure confirming the predicted pocket
    • In vivo efficacy not tested
  17. 2017 High

    Established KLF10 as a tumor-suppressive brake on EMT and a regulator of Wnt and Smad7 signaling, repressing SLUG and Smad7 via HDAC1 and acting as a β-catenin/Lef1 co-activator in bone.

    Evidence ChIP/histone-acetylation at SLUG and Smad7 promoters, Co-IP with β-catenin/Lef1, AKT/GSK-3β assays, KO bone phenotype, clinical specimens

    PMID:26801561 PMID:28108300 PMID:28201653 PMID:28249899

    Open questions at the time
    • Context-dependence of Smad7 repression (pro- vs anti-TGF-β outcomes) across tissues not reconciled
  18. 2017 High

    Defined KLF10 as a hepatic gluconeogenic driver by directly activating PGC-1α, providing a therapeutic target for hyperglycemia.

    Evidence ChIP and luciferase at Pgc-1α promoter, adenoviral gain/loss in hepatocytes and liver, glucose/pyruvate tolerance tests in diabetic mice

    PMID:28836014

    Open questions at the time
    • Integration with circadian Pepck regulation not directly addressed
  19. 2021 High

    Resolved KLF10's role in fatty liver disease, showing it activates SREBP-1C-repressive and zDHHC7/CD36-palmitoylation pathways under AMPK control, with opposing lipogenic and protective outcomes.

    Evidence AMPK phosphorylation of Thr189, ChIP at SREBP-1C and zDHHC7 promoters, CD36 palmitoylation/membrane fractionation, hepatocyte-specific KO NAFLD/NASH models

    PMID:34869587 PMID:35492028

    Open questions at the time
    • Reconciling KLF10 as both lipogenesis-suppressing (SREBP-1C) and NASH-promoting (zDHHC7/CD36) within one tissue not fully integrated
  20. 2022 High

    Linked KLF10 in T cells to organ fibrosis, showing it represses IL-9 via HDAC1 and that its loss drives perivascular fibrosis reversible by anti-IL9 antibody.

    Evidence ChIP at IL-9 promoter, HDAC1 Co-IP, CD4-specific KO Ang II model, aortic scRNA-seq, antibody rescue

    PMID:35440172

    Open questions at the time
    • Whether IL-9 repression depends on the same TGF-β feedback loop as Foxp3 not established
  21. 2024 High

    Identified an exercise-responsive cAMP/PKA/CREB → KLF10 → fumarate hydratase axis that lowers fumarate and H3K4me3 on lipogenic genes to protect against NASH.

    Evidence Hepatocyte-specific KO/overexpression mice, treadmill exercise, pathway inhibitors, fumarate metabolomics, H3K4me3 ChIP

    PMID:38615945

    Open questions at the time
    • Whether Fh1 is a direct KLF10 transcriptional target versus indirect not fully resolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • How KLF10 selects activation versus repression at a given target, and which cofactor/phosphorylation state dictates the choice in each tissue, remains the central unresolved question.
  • No structural model of KLF10 bound to coactivator vs corepressor complexes
  • No genome-wide occupancy map distinguishing activated vs repressed loci
  • Logic integrating Thr93/Thr189/Tyr179 phosphomarks with transcriptional output undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 10 GO:0003677 DNA binding 3
Localization
GO:0005634 nucleus 2 GO:0005829 cytosol 1
Pathway
R-HSA-1430728 Metabolism 5 R-HSA-168256 Immune System 5 R-HSA-4839726 Chromatin organization 5 R-HSA-74160 Gene expression (Transcription) 5 R-HSA-162582 Signal Transduction 4 R-HSA-5357801 Programmed Cell Death 4 R-HSA-9909396 Circadian clock 2
Partners
CTNNB1HDAC1ITCHJARID1BLEF1PCAFPIN1RUNX2

Evidence

Reading pass · 51 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1997 Overexpression of TIEG1/KLF10 in TGF-β-sensitive PANC1 pancreatic epithelial cells is sufficient to induce apoptosis, establishing KLF10 as a downstream effector linking TGF-β signaling to cell death. Stable overexpression in PANC1 cells with functional apoptosis readout The Journal of clinical investigation Medium 9153278
1999 TIEG1/KLF10 contains three conserved transcriptional repressor domains (R1: 10 aa, R2: 12 aa, R3: ~80 aa) outside the zinc finger DNA-binding domain that are functionally conserved between TIEG1 and TIEG2, as defined by extensive mutagenesis and GAL4-based transcriptional assays. Extensive mutagenesis combined with GAL4-based transcriptional reporter assays The Journal of biological chemistry High 10506214
1999 TIEG1/KLF10-induced apoptosis in Hep 3B cells proceeds via a mechanism involving increased reactive oxygen species generation and loss of mitochondrial membrane potential, preceding caspase-3 activation and glutathione depletion; the antioxidant trolox blocks both ROS and apoptosis. ROS measurement, mitochondrial membrane potential assay, caspase activity assay, antioxidant rescue experiment in Hep 3B cells Hepatology (Baltimore, Md.) High 10573529
2000 Stable overexpression of TIEG1/KLF10 in human osteosarcoma MG-63 cells mimics TGF-β action: increased alkaline phosphatase activity, decreased osteocalcin mRNA/protein, and decreased cell proliferation, without additive effect upon TGF-β treatment. Stable transfection of TIEG cDNA in MG-63 cells with gene expression and proliferation assays The Journal of biological chemistry Medium 10816551
2003 The zinc finger domain of TIEG1/KLF10 binds a GT-rich consensus core sequence (5'-GGTGTG-3') as established by iterative nitrocellulose filter-binding selection from a random oligonucleotide library and mutational analysis. In vitro selection from random oligonucleotide library (SELEX-like), nitrocellulose filter binding, mutational analysis of binding site DNA and cell biology High 12804117
2003 Nitric oxide (NO) upregulates TIEG1/KLF10 mRNA in human IMR-90 fibroblasts by stabilizing the transcript (6-fold increase in half-life), independently of TGF-β, as shown by anti-TGF-β antibody blocking and mRNA half-life measurements. Northern blotting, anti-TGF-β antibody neutralization, mRNA stability assay Free radical biology & medicine Medium 12788480
2004 TIEG1/KLF10 overexpression in oligodendroglial OLI-neu cells induces apoptosis by repressing Bcl-XL expression and enhancing SMAD-dependent TGF-β signaling, while reducing SMAD7 promoter activity. Overexpression in OLI-neu cells, apoptosis ELISA, DNA fragmentation, caspase-3 assay, luciferase reporter for SMAD7 promoter Journal of neuroscience research Medium 14743447
2005 TIEG1/KLF10 knockout osteoblasts are defective in BMP2-induced mineralization in vitro and show decreased RANKL and increased OPG expression, resulting in impaired support of osteoclast differentiation. TIEG1 knockout mouse calvarial osteoblast culture, BMP2 treatment, mineralization nodule assay, osteoclast co-culture with RANKL/M-CSF rescue Molecular and cellular biology High 15657444
2007 BMP2 opposes Shh-mediated proliferation in cerebellar granule neuron precursors by inducing TIEG1/KLF10, which occupies Sp1 sites in the N-myc promoter and blocks N-myc expression, leading to cell cycle arrest. Chromatin occupancy at Nmyc promoter, ectopic TIEG1 expression in cerebellar granule neuron precursors, cell cycle analysis The Journal of biological chemistry Medium 17951258
2007 TIEG1/KLF10 induces apoptosis through the mitochondrial pathway in K562 leukemia cells, involving Bax and Bim up-regulation, Bcl-2 and Bcl-XL down-regulation, cytochrome c release, caspase-3 activation, and mitochondrial membrane potential disruption. TIEG1 overexpression in K562 cells, Western blotting for Bcl-2 family members, cytochrome c release assay, caspase-3 activity, mitochondrial membrane potential measurement FEBS letters Medium 17659279
2008 The E3 ubiquitin ligase Itch associates with TIEG1/KLF10 and promotes its non-proteolytic K63-linked ubiquitination; this cooperates with TIEG1 to induce Foxp3 expression in T cells, and TGF-β-converted Tregs from TIEG1-deficient mice fail to suppress airway inflammation. Co-immunoprecipitation, ubiquitination assay, Itch-/- and TIEG1-/- mouse T cell functional studies, in vivo airway inflammation model Nature immunology High 18278048
2008 KLF10 directly transactivates both the TGF-β1 and Foxp3 promoters in CD4+ T cells in response to TGF-β1, forming a positive feedback loop; KLF10-/- CD4+CD25- T cells show enhanced Th1/Th2 differentiation and cannot be suppressed by wild-type Tregs, while KLF10-/- Tregs have reduced TGF-β1 production and suppressor function rescued by exogenous TGF-β1. KLF10 KO mouse CD4+ T cell functional studies, promoter transactivation assays, Th1/Th2 cytokine profiling, atherosclerosis model The Journal of biological chemistry High 19602726
2008 KLF10 is a VHL target gene; KLF10 transactivates the TGFBI (BIGH3) promoter as assessed by luciferase reporter assay, establishing KLF10 as an intermediate between VHL status and ECM gene expression in clear cell carcinoma. Expression arrays, luciferase reporter assay of TGFBI promoter with KLF10 co-transfection, cell lines with different VHL status Biochemical and biophysical research communications Medium 18359287
2010 TIEG1/KLF10 directly binds the Bmal1 promoter through two juxtaposed GC boxes near the transcription initiation site and represses Bmal1 transcription; siRNA knockdown of TIEG1 causes period shortening in cellular bioluminescence rhythms driven by Bmal1-luciferase and Per2-luciferase reporters. In vitro transcription assay, luciferase reporter with mutational analysis, siRNA knockdown, real-time bioluminescence circadian assay Genes to cells : devoted to molecular & cellular mechanisms High 20070857
2010 KLF10 displays circadian expression in mouse liver driven by CLOCK-BMAL1; the Klf10 promoter recruits BMAL1 and is transactivated by CLOCK-BMAL1 through a conserved E-box. KLF10 deficiency in liver causes postprandial/fasting hyperglycemia with upregulation of Pepck; KLF10 directly represses the Pepck promoter. KLF10 KO mice, Bmal1 KO mice, chromatin immunoprecipitation of BMAL1 at Klf10 promoter, liver transcriptome profiling, luciferase reporter for Pepck promoter, hepatic glucose production assay Molecular and cellular biology High 20385766
2010 JARID1B/KDM5B is a corepressor of TIEG1/KLF10: the repression domains of TIEG1 bind the C-terminus of JARID1B. JARID1B overexpression augments TIEG1-mediated repression of Smad7; JARID1B knockdown increases Smad7 mRNA, indicating TIEG1 represses transcription through histone H3K4 demethylation. Co-immunoprecipitation (TIEG1–JARID1B), domain mapping, Smad7 reporter assay with JARID1B overexpression/knockdown Biochemical and biophysical research communications Medium 20863814
2011 IL-6 activates Tyk2, which phosphorylates TIEG1/KLF10 at Tyr179, promoting non-canonical K27-linked polyubiquitination that inhibits TIEG1 nuclear translocation and thereby abrogates TGF-β-induced Treg development. Phosphorylation assays, ubiquitination assays, nuclear fractionation, functional Treg development assay, TRAMP-C2 tumor model in TIEG1-/- mice Journal of immunology High 21471442
2011 TIEG1/KLF10 directly binds to and activates the Runx2 promoter (via its zinc finger domain) and physically associates with Runx2 protein to co-activate Runx2 transcriptional activity; TGF-β1 and BMP2 induction of Runx2 requires TIEG1 expression. Transient transfection with promoter deletion constructs, chromatin immunoprecipitation, co-immunoprecipitation, adenoviral Runx2 rescue in KO osteoblasts PloS one High 21559363
2011 TIEG1/KLF10 suppresses breast cancer cell invasion and mammary tumorigenesis by directly binding to the EGFR promoter at Sp1 sites, recruiting HDAC1, suppressing histone acetylation, and thereby inhibiting EGFR transcription. TIEG1 overexpression/knockdown, chromatin immunoprecipitation, co-immunoprecipitation of TIEG1-HDAC1 complex, EGFR promoter binding, invasion assay, xenograft model Molecular and cellular biology High 22025675
2011 Klf10 directly modulates transcription of BI-1 (Bax inhibitor-1) by binding to the BI-1 promoter, as confirmed by ChIP-chip, EMSA, and BI-1 promoter mutation that abolishes Klf10-mediated repression; reduced BI-1 increases cytosolic Ca2+ and induces apoptosis in estrogen-responding breast cancer cells. ChIP-chip, EMSA, BI-1 promoter luciferase with binding site mutation, si-KLF10 rescue, intracellular Ca2+ measurement The international journal of biochemistry & cell biology High 21262377
2012 KLF10 dose-dependently activates p21WAF1/CIP1 transcription independently of p53 and Sp1 binding sites, and KLF10-deficient mice exhibit increased susceptibility to skin tumorigenesis after DMBA/TPA treatment. KLF10 KO mouse tumorigenesis model, p21 promoter luciferase assay with deletion/mutation, colony formation assay after H-Ras transfection Biochemical and biophysical research communications Medium 22349513
2013 KLF10 stability is regulated by RAF-1-mediated phosphorylation at Thr93 and subsequent interaction with the prolyl isomerase PIN1 (identified by yeast two-hybrid); PIN1 binding (phosphorylation-dependent, via the pThr93-Pro motif) promotes KLF10 protein degradation. In vitro and in vivo phosphorylation assays, yeast two-hybrid screening, site-directed mutagenesis of Thr93, protein-protein interaction assays, cycloheximide chase, in vitro kinase assay with RAF-1 Biochimica et biophysica acta High 23994618
2013 KLF10 represses FGFR1 promoter activity in myoblasts by binding to the proximal Sp1 binding site of the FGFR1 promoter, competing with Sp1, thereby reducing myoblast proliferation by 86%. Southwestern blot, electromobility shift assay (EMSA), chromatin immunoprecipitation, FGFR1 promoter luciferase in myoblasts and Drosophila SL2 cells, cell proliferation assay The Journal of biological chemistry High 23569208
2014 KLF10 directly binds to the TGF-βRII promoter in CD8+ T cells, activating its transcription; KLF10-deficient CD8+ T cells show reduced TGF-βRII surface expression and attenuated Smad2 phosphorylation after TGF-β1 stimulation. Chromatin immunoprecipitation, TGF-βRII promoter binding assay, KLF10-/- mouse CD8+ T cell phenotyping, flow cytometry for TGF-βRII, phospho-Smad2 measurement, in vivo viral infection model American journal of physiology. Cell physiology High 25472963
2014 KLF10 integrates antagonistic epigenetic signals at the FOXP3 promoter: an NH2-terminal Sin3-interacting repressor domain limits KLF10 activation, while inactivation of this domain enables KLF10 to physically associate with the histone acetyltransferase PCAF to induce FOXP3 gene transcription. Chromatin immunoprecipitation, genome-integrated reporter assay, functional domain KLF10 mutant proteins, Co-IP with PCAF and Sin3-HDAC complex, primary murine lymphocyte validation American journal of physiology. Regulatory, integrative and comparative physiology High 24944246
2015 KLF10 directly binds to the TGF-βRII promoter in macrophages, enhancing its transcription through histone H3 acetylation; KLF10-deficient macrophages show reduced TGF-βRII expression, attenuated Smad2 phosphorylation, and a pro-inflammatory cytokine profile (increased TNF-α, decreased IL-10). Chromatin immunoprecipitation, KLF10-/- mouse bone marrow-derived macrophage studies, H3 acetylation assay at TGF-βRII promoter, cytokine ELISA, adoptive transfer of KO macrophages American journal of physiology. Gastrointestinal and liver physiology High 26472224
2015 KLF10 transcriptionally activates the SEI-1 promoter and induces SEI-1 protein expression in pancreatic carcinoma cells, subsequently increasing p21Cip1 expression; KLF10-deficient mice show decreased pancreatic islet mass with nuclear accumulation of p21Cip1. ChIP-chip identification of SEI-1 as KLF10 target, luciferase promoter assay, KLF10 KO mouse islet histology The international journal of biochemistry & cell biology Medium 25578559
2016 TIEG1/KLF10 directly binds to and activates the Osterix promoter (via its zinc finger DNA-binding domain) in osteoblasts; TIEG1 is required for induction of Osterix by TGF-β1 and BMP2. Transient transfection with Osterix promoter constructs, chromatin immunoprecipitation, shRNA and CRISPR knockdown of TIEG1, KO osteoblast complementation Biochemical and biophysical research communications High 26801561
2017 KLF10 suppresses TGF-β-induced EMT by occupying GC-rich sequences in the SLUG/SNAI2 promoter, recruiting HDAC1, and removing activating histone acetylation marks to repress SLUG transcription. KLF10 depletion (siRNA/shRNA), chromatin immunoprecipitation at SLUG promoter, histone acetylation assay, EMT marker panel, lung adenocarcinoma clinical specimens Cancer research High 28249899
2017 TIEG1/KLF10 directly represses Smad7 promoter activity by binding a GC-box/Sp1 site at nucleotides -1392 to -1382, thereby promoting Smad2 phosphorylation and enhancing TGF-β/Smad signaling in keloid fibroblasts. siRNA knockdown and overexpression, luciferase reporter assay of Smad7 promoter, chromatin immunoprecipitation, collagen production and migration assays The Journal of investigative dermatology High 28108300
2017 TIEG1/KLF10 is involved in canonical Wnt signaling in bone: TIEG1 modulates AKT and GSK-3β activity to promote β-catenin nuclear localization, and TIEG1 physically interacts with and serves as a transcriptional co-activator for Lef1 and β-catenin. Co-immunoprecipitation (TIEG1–β-catenin, TIEG1–Lef1), subcellular fractionation, AKT/GSK-3β phosphorylation assays, KO mouse bone phenotype analysis Nucleic acids research High 28201653
2017 KLF10 directly activates PGC-1α (Ppargc1a) gene transcription by binding to its promoter region, increasing expression of gluconeogenic genes and hepatic glucose output; hepatic KLF10 knockdown in diabetic/obese mice decreases blood glucose. Luciferase reporter gene assay, chromatin immunoprecipitation, adenoviral KLF10 overexpression/shRNA in primary hepatocytes and mouse liver, glucose tolerance and pyruvate tolerance tests Diabetologia High 28836014
2017 Loss of KLF10 in pancreatic cancer cooperating with KrasG12D increases distant metastases and cancer stemness through activation of SDF-1/CXCR4 and AP-1 pathways; inhibition of the SDF-1/CXCR4 pathway suppresses PDAC progression in KLF10-null context. Pdx-1Cre KrasG12D KLF10 conditional KO mouse models, SDF-1/CXCR4 pathway analysis, CXCR4 inhibitor treatment Oncogene Medium 28581520
2018 KDM6A (a histone lysine demethylase) upregulates KLF10 in diabetic podocytes, and KLF10 in turn represses nephrin expression by directly binding the nephrin gene promoter and recruiting DNA methyltransferase Dnmt1; KLF10 overexpression also increases KDM6A, forming a positive feedback loop. KDM6A/KLF10 overexpression/KO in podocytes, chromatin immunoprecipitation at nephrin promoter, Dnmt1 co-recruitment assay, KDM6A/KLF10 KO mouse diabetic nephropathy model EMBO molecular medicine High 30948420
2018 C/EBPβ binds to the KLF10 promoter and transactivates KLF10 expression during mitotic clonal expansion in 3T3-L1 preadipocytes; KLF10 in turn represses C/EBPα promoter activity by recruiting HDAC1, decreasing acetylated histone H4, thereby delaying adipogenesis. Chromatin immunoprecipitation, promoter luciferase with deletion/mutation analysis, co-immunoprecipitation (KLF10–HDAC1), siRNA knockdown, histone acetylation assay The Journal of biological chemistry High 30026232
2010 HPV-16 E7 directly binds the C-terminus of TIEG1/KLF10 (identified by yeast two-hybrid) and promotes TIEG1 degradation via the ubiquitin pathway, attenuating TIEG1-mediated apoptosis. Yeast two-hybrid, co-immunoprecipitation, ubiquitination assay, apoptosis functional assay The international journal of biochemistry & cell biology Medium 20691807
2020 CD4+-T-cell-specific KLF10 knockout mice develop obesity, insulin resistance, and fatty liver due to defects in Treg mobilization to liver/adipose tissue and decreased TGF-β3 release; mechanistically, KLF10 KO Tregs exhibit reduced mitochondrial respiration, glycolysis, and PI3K-Akt-mTOR signaling, impairing chemotaxis. Adoptive transfer of WT Tregs fully rescues the phenotype. CD4+-T-cell-specific KLF10 KO mice, metabolic phenotyping, Treg adoptive transfer rescue, in vitro TGF-β3 ELISA, metabolic flux analysis (mitochondrial respiration and glycolysis), PI3K-Akt-mTOR signaling assays Cell reports High 33378664
2021 KLF10 promotes NASH progression by transcriptionally activating zDHHC7, which palmitoylates CD36 to promote its plasma membrane localization and hepatic lipid accumulation; both zDHHC7 expression and CD36 palmitoylation are required for KLF10's pathogenic role. Hepatocyte-specific KLF10 overexpression/depletion in NASH mouse models, transcriptomic analysis, luciferase reporter and ChIP for zDHHC7 promoter, CD36 palmitoylation assay, plasma membrane fractionation EMBO reports High 35492028
2021 AMPK phosphorylates KLF10 at Thr189, stabilizing the protein; phosphorylated KLF10 binds the SREBP-1C promoter and represses its transcription, thereby reducing lipogenesis. Hepatic-specific KLF10 KO mice develop more severe NAFLD on a high-fat diet. In vitro and in vivo phosphorylation assays, ChIP-chip for target gene identification, SREBP-1C promoter luciferase, hepatocyte-specific KLF10 KO mouse NAFLD model, Western blotting Frontiers in molecular biosciences High 34869587
2021 KLF10 binds to the IL-9 promoter and interacts with HDAC1 to inhibit IL-9 transcription in CD4+ T cells; CD4+-T-cell-specific KLF10 deficiency leads to increased IL-9, which drives fibroblast activation, calcium mobilization, and perivascular fibrosis; anti-IL9 antibodies reverse the fibrosis. Chromatin immunoprecipitation (KLF10 at IL-9 promoter, HDAC1 interaction), TKO mouse Ang II infusion model, aortic single-cell RNA-seq, cytokine analysis, anti-IL9 therapeutic rescue Circulation research High 35440172
2024 Exercise induces KLF10 expression in liver via the cAMP/PKA/CREB pathway; KLF10 promotes fumarate hydratase 1 (Fh1) expression, thereby reducing fumarate accumulation, decreasing H3K4me3 on lipogenic gene promoters, and attenuating lipogenesis to protect against NASH. Hepatocyte-specific KLF10 KO and overexpression mouse models, treadmill exercise, cAMP/PKA/CREB pathway inhibitors, fumarate metabolomics, H3K4me3 ChIP at lipogenic gene promoters Metabolism: clinical and experimental High 38615945
2015 Computer-aided drug design identified small molecule inhibitors that bind a druggable pocket in the second zinc finger of KLF10, inhibiting KLF10-DNA binding and transcriptional activity, as well as conversion of CD4+CD25- T cells to CD4+CD25+ Tregs. CADD virtual screening, KLF10-DNA binding inhibition assays, T regulatory cell conversion assay, KLF10 target gene expression Journal of medicinal chemistry Medium 25581017
2022 KLF10 directly binds the ACSM3 promoter and transcriptionally activates it (validated by ChIP and dual-luciferase assay); KLF10-mediated ACSM3 upregulation inhibits PI3K/Akt signaling to suppress melanoma cell proliferation, invasion, and migration. ChIP assay, dual-luciferase reporter, KLF10 overexpression and ACSM3 knockdown rescue experiments, PI3K/Akt phosphorylation assays Oncology letters Medium 35497935
2019 KLF10 directly regulates the Indian hedgehog (Ihh) promoter activity in mesenchymal stem cells; KLF10 knockdown mimics miR-892b overexpression in enhancing chondrogenesis and inhibiting hypertrophy in TGF-β-mediated chondrogenesis. Luciferase assay for Ihh promoter, KLF10 knockdown in hMSC chondrogenesis, miR-892b mimic overexpression, hypertrophic and chondrogenic marker gene analysis Molecular therapy. Nucleic acids Medium 31284128
2012 TIEG1/KLF10 missense mutations found in human HCM patients significantly increase PTTG1 promoter activity in transfection/luciferase assays compared to WT TIEG1, and PTTG1 protein is elevated in TIEG1-mutation-positive HCM cardiac tissue by immunohistochemistry. Site-directed mutagenesis, transient transfection luciferase assay for PTTG1 promoter, immunohistochemistry of cardiac tissue Journal of cellular biochemistry Medium 22234868
2015 TIEG1/KLF10 inhibits Ang II-induced cardiomyocyte hypertrophy by inhibiting the expression and transcriptional activity of GATA4; TIEG1 knockdown upregulates ANF and BNP, while TIEG1 overexpression inhibits hypertrophic gene expression. siRNA knockdown and overexpression in cardiomyocytes, cellular surface area measurement, ANF/BNP mRNA quantification, GATA4 transcriptional activity assay Journal of cardiovascular pharmacology Medium 26252173
2017 TIEG1/KLF10 directly suppresses SOST (sclerostin) promoter activity; TIEG1 KO osteocytes (shRNA or CRISPR-Cas9) show increased SOST expression and delayed mineralization. Estrogen and ovariectomy modulate SOST expression in a TIEG1-dependent manner in vivo. Promoter deletion assay, chromatin immunoprecipitation, shRNA and CRISPR-Cas9 knockdown in IDG-SW3 osteocytes, OVX/ERT studies with mRNA sequencing Journal of cellular physiology High 29044507
2012 TIEG1/KLF10 represses stathmin promoter activity in a dose-dependent manner and is required for TGF-β1-induced growth inhibition in hepatocellular carcinoma cells; siRNA knockdown of TIEG1 decreases TGF-β1 sensitivity in Hep3B cells. siRNA knockdown, TIEG1 lentiviral overexpression, luciferase assay for stathmin promoter, MTT cell viability assay, DAPI apoptosis staining World journal of gastroenterology Medium 22563190
2016 KLF10 acts as a transcriptional repressor of NPRA and directly binds the NPRA promoter; KLF10-deficient mice show increased NPRA expression and exacerbated pulmonary inflammation upon LPS or ovalbumin challenge. KLF10 KO mouse pulmonary inflammation model, luciferase reporter assay showing KLF10 repression of NPRA promoter, ChIP confirming KLF10 binding to NPRA promoter, histology The international journal of biochemistry & cell biology Medium 27592451
2022 KLF10 directly binds the promoter of LINC00629 (confirmed by ChIP) and activates its transcription; apigenin induces KLF10 which then drives LINC00629 expression to decrease Mcl1 stability and promote apoptosis in oral squamous cell carcinoma. Chromatin immunoprecipitation of KLF10 at LINC00629 promoter, luciferase reporter assay, LINC00629-Mcl1 protein interaction and degradation assays Aging Medium 36445338
2020 KLF10 deletion in liver leads to increased phosphorylation and nuclear localization of Smad3 under high-sucrose feeding, contributing to liver fibrosis; KLF10 depletion sensitizes primary hepatocytes to TNF-α-induced apoptosis via increased caspase-3 activation. Klf10 KO mouse high-sucrose diet model, Smad3 phosphorylation and nuclear localization Western blot/immunofluorescence, primary hepatocyte apoptosis with TNF-α treatment, caspase-3 assay International journal of molecular sciences Medium 33396939

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1997 Overexpression of the TGFbeta-regulated zinc finger encoding gene, TIEG, induces apoptosis in pancreatic epithelial cells. The Journal of clinical investigation 200 9153278
2008 The E3 ubiquitin ligase Itch regulates expression of transcription factor Foxp3 and airway inflammation by enhancing the function of transcription factor TIEG1. Nature immunology 148 18278048
1999 The transforming growth factor beta(1)-inducible transcription factor TIEG1, mediates apoptosis through oxidative stress. Hepatology (Baltimore, Md.) 142 10573529
2017 LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma. Cell death & disease 135 28796257
1999 Three conserved transcriptional repressor domains are a defining feature of the TIEG subfamily of Sp1-like zinc finger proteins. The Journal of biological chemistry 105 10506214
2010 Functional role of KLF10 in multiple disease processes. BioFactors (Oxford, England) 100 20087894
2005 TIEG1 null mouse-derived osteoblasts are defective in mineralization and in support of osteoclast differentiation in vitro. Molecular and cellular biology 98 15657444
2010 Kruppel-like factor KLF10 is a link between the circadian clock and metabolism in liver. Molecular and cellular biology 97 20385766
2021 Hypoxic tumour cell-derived exosomal miR-340-5p promotes radioresistance of oesophageal squamous cell carcinoma via KLF10. Journal of experimental & clinical cancer research : CR 88 33485367
2009 Kruppel-like factor KLF10 targets transforming growth factor-beta1 to regulate CD4(+)CD25(-) T cells and T regulatory cells. The Journal of biological chemistry 88 19602726
2018 KLF10 as a Tumor Suppressor Gene and Its TGF-β Signaling. Cancers 79 29799499
2000 TIEG proteins join the Smads as TGF-beta-regulated transcription factors that control pancreatic cell growth. American journal of physiology. Gastrointestinal and liver physiology 78 10762604
2011 Klf10 and Klf11 as mediators of TGF-beta superfamily signaling. Cell and tissue research 70 21574058
2000 Overexpression of a nuclear protein, TIEG, mimics transforming growth factor-beta action in human osteoblast cells. The Journal of biological chemistry 70 10816551
2007 Role of TIEG1 in biological processes and disease states. Journal of cellular biochemistry 69 17729309
2004 Dual functions of transcription factors, transforming growth factor-beta-inducible early gene (TIEG)2 and Sp3, are mediated by CACCC element and Sp1 sites of human monoamine oxidase (MAO) B gene. The Journal of biological chemistry 61 15024015
2019 A KDM6A-KLF10 reinforcing feedback mechanism aggravates diabetic podocyte dysfunction. EMBO molecular medicine 60 30948420
2007 Bone morphogenetic protein 2 opposes Shh-mediated proliferation in cerebellar granule cells through a TIEG-1-based regulation of Nmyc. The Journal of biological chemistry 60 17951258
2020 Deletion of KLF10 Leads to Stress-Induced Liver Fibrosis upon High Sucrose Feeding. International journal of molecular sciences 56 33396939
2011 TIEG1 inhibits breast cancer invasion and metastasis by inhibition of epidermal growth factor receptor (EGFR) transcription and the EGFR signaling pathway. Molecular and cellular biology 54 22025675
2008 Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors. Biochemical and biophysical research communications 54 18359287
2007 TGFbeta inducible early gene-1 (TIEG1) and cardiac hypertrophy: Discovery and characterization of a novel signaling pathway. Journal of cellular biochemistry 52 16888812
2017 Krüppel-like Transcription Factor KLF10 Suppresses TGFβ-Induced Epithelial-to-Mesenchymal Transition via a Negative Feedback Mechanism. Cancer research 51 28249899
2010 Histone demethylase JARID1B/KDM5B is a corepressor of TIEG1/KLF10. Biochemical and biophysical research communications 48 20863814
2016 Zinc supplementation induces CD4+CD25+Foxp3+ antigen-specific regulatory T cells and suppresses IFN-γ production by upregulation of Foxp3 and KLF-10 and downregulation of IRF-1. European journal of nutrition 47 27260002
2008 Estrogen-TGFbeta cross-talk in bone and other cell types: role of TIEG, Runx2, and other transcription factors. Journal of cellular biochemistry 45 17541956
2017 TIEG1 Represses Smad7-Mediated Activation of TGF-β1/Smad Signaling in Keloid Pathogenesis. The Journal of investigative dermatology 44 28108300
2008 TIEG-null mice display an osteopenic gender-specific phenotype. Bone 43 18396127
2020 KLF10 Deficiency in CD4+ T Cells Triggers Obesity, Insulin Resistance, and Fatty Liver. Cell reports 42 33378664
2011 Noncanonical K27-linked polyubiquitination of TIEG1 regulates Foxp3 expression and tumor growth. Journal of immunology (Baltimore, Md. : 1950) 39 21471442
2007 TIEG1 induces apoptosis through mitochondrial apoptotic pathway and promotes apoptosis induced by homoharringtonine and velcade. FEBS letters 38 17659279
2000 Cytokine-specific induction of the TGF-beta inducible early gene (TIEG): regulation by specific members of the TGF-beta family. Journal of cellular biochemistry 38 10861837
2013 Repression of myoblast proliferation and fibroblast growth factor receptor 1 promoter activity by KLF10 protein. The Journal of biological chemistry 37 23569208
2011 TIEG1/KLF10 modulates Runx2 expression and activity in osteoblasts. PloS one 37 21559363
2018 Krüppel-like factor 10 (KLF10) is transactivated by the transcription factor C/EBPβ and involved in early 3T3-L1 preadipocyte differentiation. The Journal of biological chemistry 36 30026232
2011 Klf10 induces cell apoptosis through modulation of BI-1 expression and Ca2+ homeostasis in estrogen-responding adenocarcinoma cells. The international journal of biochemistry & cell biology 36 21262377
2017 KLF10 transcription factor regulates hepatic glucose metabolism in mice. Diabetologia 34 28836014
2010 Transcriptional repressor TIEG1 regulates Bmal1 gene through GC box and controls circadian clockwork. Genes to cells : devoted to molecular & cellular mechanisms 31 20070857
2012 KLF10, transforming growth factor-β-inducible early gene 1, acts as a tumor suppressor. Biochemical and biophysical research communications 30 22349513
2007 The role of STAT, AP-1, E-box and TIEG motifs in the regulation of hepcidin by IL-6 and BMP-9: lessons from human HAMP and murine Hamp1 and Hamp2 gene promoters. Blood cells, molecules & diseases 29 17689119
2017 KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the KrasG12D p53flox/flox model. Oncogene 28 28581520
2015 Klf10 regulates odontoblast differentiation and mineralization via promoting expression of dentin matrix protein 1 and dentin sialophosphoprotein genes. Cell and tissue research 27 26310138
2014 Krüppel-like factor KLF10 regulates transforming growth factor receptor II expression and TGF-β signaling in CD8+ T lymphocytes. American journal of physiology. Cell physiology 27 25472963
2004 TIEG1 facilitates transforming growth factor-beta-mediated apoptosis in the oligodendroglial cell line OLI-neu. Journal of neuroscience research 27 14743447
1998 TGFbeta-inducible early gene (TIEG) also codes for early growth response alpha (EGRalpha): evidence of multiple transcripts from alternate promoters. Genomics 27 9721211
2022 KLF10 promotes nonalcoholic steatohepatitis progression through transcriptional activation of zDHHC7. EMBO reports 26 35492028
2014 Differential coupling of KLF10 to Sin3-HDAC and PCAF regulates the inducibility of the FOXP3 gene. American journal of physiology. Regulatory, integrative and comparative physiology 25 24944246
2013 Destabilization of KLF10, a tumor suppressor, relies on thr93 phosphorylation and isomerase association. Biochimica et biophysica acta 25 23994618
2012 TGFβ-inducible early gene-1 (TIEG1) mutations in hypertrophic cardiomyopathy. Journal of cellular biochemistry 25 22234868
2022 Krüppel-like factor 10 (KLF10) as a critical signaling mediator: Versatile functions in physiological and pathophysiological processes. Genes & diseases 24 37396542
2016 Impact of TIEG1 Deletion on the Passive Mechanical Properties of Fast and Slow Twitch Skeletal Muscles in Female Mice. PloS one 24 27736981
2015 Krüppel-like factor KLF10 deficiency predisposes to colitis through colonic macrophage dysregulation. American journal of physiology. Gastrointestinal and liver physiology 24 26472224
2022 Perivascular Fibrosis Is Mediated by a KLF10-IL-9 Signaling Axis in CD4+ T Cells. Circulation research 23 35440172
2021 Positive feedback between lncRNA FLVCR1-AS1 and KLF10 may inhibit pancreatic cancer progression via the PTEN/AKT pathway. Journal of experimental & clinical cancer research : CR 23 34635142
2020 Salvia miltiorrhiza bunge exerts anti-oxidative effects through inhibiting KLF10 expression in vascular smooth muscle cells exposed to high glucose. Journal of ethnopharmacology 23 32738388
2011 TIEG1 negatively controls the myoblast pool indispensable for fusion during myogenic differentiation of C2C12 cells. Journal of cellular physiology 23 20945337
2023 Exosomal ITGB6 from dormant lung adenocarcinoma cells activates cancer-associated fibroblasts by KLF10 positive feedback loop and the TGF-β pathway. Translational lung cancer research 22 38205211
2024 Hepatic Klf10-Fh1 axis promotes exercise-mediated amelioration of NASH in mice. Metabolism: clinical and experimental 21 38615945
2021 MicroRNA-26b-5p alleviates cerebral ischemia-reperfusion injury in rats via inhibiting the N-myc/PTEN axis by downregulating KLF10 expression. Human & experimental toxicology 21 33559506
2020 KLF10 inhibits cell growth by regulating PTTG1 in multiple myeloma under the regulation of microRNA-106b-5p. International journal of biological sciences 21 32549754
2017 TIEG1 modulates β-catenin sub-cellular localization and enhances Wnt signaling in bone. Nucleic acids research 21 28201653
2004 Gene structure and evolution of Tieg3, a new member of the Tieg family of proteins. Gene 21 14697507
2023 Inhibition of Klf10 Attenuates Oxidative Stress-Induced Senescence of Chondrocytes via Modulating Mitophagy. Molecules (Basel, Switzerland) 20 36770589
2021 KLF10 integrates circadian timing and sugar signaling to coordinate hepatic metabolism. eLife 20 34402428
2016 TIEG1 enhances Osterix expression and mediates its induction by TGFβ and BMP2 in osteoblasts. Biochemical and biophysical research communications 20 26801561
2012 Klf10 inhibits IL-12p40 production in macrophage colony-stimulating factor-induced mouse bone marrow-derived macrophages. European journal of immunology 20 23065757
2021 Therapeutic Targeting of Nonalcoholic Fatty Liver Disease by Downregulating SREBP-1C Expression via AMPK-KLF10 Axis. Frontiers in molecular biosciences 18 34869587
2018 MicroRNA-19 restores vascular endothelial cell function in lower limb ischemia-reperfusion injury through the KLF10-dependent TGF-β1/Smad signaling pathway in rats. Journal of cellular biochemistry 18 29953651
2019 Novel role of Tieg1 in muscle metabolism and mitochondrial oxidative capacities. Acta physiologica (Oxford, England) 17 31560161
2017 TIEG1 deficiency confers enhanced myocardial protection in the infarcted heart by mediating the Pten/Akt signalling pathway. International journal of molecular medicine 17 28204828
2016 Klf10 deficiency in mice exacerbates pulmonary inflammation by increasing expression of the proinflammatory molecule NPRA. The international journal of biochemistry & cell biology 17 27592451
2008 Bone marrow stroma cells regulate TIEG1 expression in acute lymphoblastic leukemia cells: role of TGFbeta/BMP-6 and TIEG1 in chemotherapy escape. International journal of cancer 17 18798273
2007 Minor contribution of SMAD7 and KLF10 variants to genetic susceptibility of type 2 diabetes. Diabetes & metabolism 17 17931948
2015 KLF10 affects pancreatic function via the SEI-1/p21Cip1 pathway. The international journal of biochemistry & cell biology 16 25578559
2015 Discovery of small molecule inhibitors to Krüppel-like factor 10 (KLF10): implications for modulation of T regulatory cell differentiation. Journal of medicinal chemistry 16 25581017
2012 Transactivation of the TIEG1 confers growth inhibition of transforming growth factor-β-susceptible hepatocellular carcinoma cells. World journal of gastroenterology 16 22563190
2011 Drosophila TIEG is a modulator of different signalling pathways involved in wing patterning and cell proliferation. PloS one 16 21494610
2003 Nitric oxide-mediated upregulation of the TGF-beta-inducible early response gene-1 (TIEG1) in human fibroblasts by mRNA stabilization independent of TGF-beta. Free radical biology & medicine 16 12788480
2020 KLF10 is a modulatory factor of chondrocyte hypertrophy in developing skeleton. Journal of orthopaedic research : official publication of the Orthopaedic Research Society 15 32144802
2020 MCD diet-induced steatohepatitis generates a diurnal rhythm of associated biomarkers and worsens liver injury in Klf10 deficient mice. Scientific reports 15 32699233
2022 KLF10 deficiency in CD4+ T cells promotes atherosclerosis progression by altering macrophage dynamics. Atherosclerosis 14 36174463
2016 Impact of TIEG1 on the structural properties of fast- and slow-twitch skeletal muscle. Muscle & nerve 14 27421714
2016 KLF10 Mediated Epigenetic Dysregulation of Epithelial CD40/CD154 Promotes Endometriosis. Biology of reproduction 14 27488034
2015 Effect of TIEG1 on apoptosis and expression of Bcl-2/Bax and Pten in leukemic cell lines. Genetics and molecular research : GMR 14 25867342
2010 Tieg1/Klf10 is upregulated by NGF and attenuates cell cycle progression in the pheochromocytoma cell line PC12. Journal of neuroscience research 14 20155803
2003 Identification and characterization of a consensus DNA binding element for the zinc finger transcription factor TIEG/EGRalpha. DNA and cell biology 14 12804117
2020 KLF10 is upregulated in osteoarthritis and inhibits chondrocyte proliferation and migration by upregulating Acvr1 and suppressing inhbb expression. Acta histochemica 13 32156482
2010 Possible role of TIEG1 as a feedback regulator of myostatin and TGF-beta in myoblasts. Biochemical and biophysical research communications 13 20171187
2022 KLF10 upregulates ACSM3 via the PI3K/Akt signaling pathway to inhibit the malignant progression of melanoma. Oncology letters 12 35497935
2022 LINC00629, a KLF10-responsive lncRNA, promotes the anticancer effects of apigenin by decreasing Mcl1 stability in oral squamous cell carcinoma. Aging 12 36445338
2021 Effect of Photodynamic Therapy on Gemcitabine-Resistant Cholangiocarcinoma in vitro and in vivo Through KLF10 and EGFR. Frontiers in cell and developmental biology 12 34805140
2019 miR-892b Inhibits Hypertrophy by Targeting KLF10 in the Chondrogenesis of Mesenchymal Stem Cells. Molecular therapy. Nucleic acids 12 31284128
2010 Molecular structure of tail tendon fibers in TIEG1 knockout mice using synchrotron diffraction technology. Journal of applied physiology (Bethesda, Md. : 1985) 12 20378701
2024 Klf10 is involved in extracellular matrix calcification of chondrocytes alleviating chondrocyte senescence. Journal of translational medicine 11 38217021
2022 Knockout of KLF10 Ameliorated Diabetic Renal Fibrosis via Downregulation of DKK-1. Molecules (Basel, Switzerland) 11 35565995
2017 Klf10 Gene, a Secondary Modifier and a Pharmacogenomic Biomarker of Hydroxyurea Treatment Among Patients With Hemoglobinopathies. Journal of pediatric hematology/oncology 11 28085748
2002 Absence of mutations in the transforming growth factor-beta inducible early gene 1, TIEG1, in pancreatic cancer. Cancer letters 11 12065093
2017 TIEG and estrogen modulate SOST expression in the murine skeleton. Journal of cellular physiology 10 29044507
2015 TIEG1 Inhibits Angiotensin II-induced Cardiomyocyte Hypertrophy by Inhibiting Transcription Factor GATA4. Journal of cardiovascular pharmacology 10 26252173
2010 The human papillomavirus-16 (HPV-16) oncoprotein E7 conjugates with and mediates the role of the transforming growth factor-beta inducible early gene 1 (TIEG1) in apoptosis. The international journal of biochemistry & cell biology 10 20691807

Missed literature

Know a paper Affinage missed for KLF10? Flag it for the maintainers and the community.

No submissions yet.